Back to Search
Start Over
Preoperative Treatment With Pazopanib in a Case of Chemotherapy-Resistant Infantile Fibrosarcoma.
- Source :
-
Pediatric blood & cancer [Pediatr Blood Cancer] 2016 Feb; Vol. 63 (2), pp. 348-51. Date of Electronic Publication: 2015 Sep 16. - Publication Year :
- 2016
-
Abstract
- Clinical and radiological diagnosis of infantile fibrosarcoma (IFS) is challenging because of its similarity to vascular origin tumors. Treatment involves complete resection. Although chemotherapy may allow more conservative resection, treatment guidelines are not strictly defined. One IFS patient with an unresectable tumor had disease progression during chemotherapy. A primary tumor sample showed high VEGFR-1/2/3 and PDGFR-α/β expression. After pazopanib therapy, most tumor showed necrosis within 29 days and could be removed completely, with no relapse in 8 months post-resection. When IFS features hypervascularity, VEGFR and PDGFR expression may be high, thus allowing consideration of VEGFR inhibitors such as pazopanib.<br /> (© 2015 Wiley Periodicals, Inc.)
- Subjects :
- Axilla pathology
Drug Resistance, Neoplasm
Fibrosarcoma pathology
Humans
Indazoles
Infant
Male
Receptors, Platelet-Derived Growth Factor antagonists & inhibitors
Receptors, Platelet-Derived Growth Factor biosynthesis
Receptors, Vascular Endothelial Growth Factor antagonists & inhibitors
Receptors, Vascular Endothelial Growth Factor biosynthesis
Reverse Transcriptase Polymerase Chain Reaction
Angiogenesis Inhibitors therapeutic use
Fibrosarcoma drug therapy
Neoadjuvant Therapy methods
Pyrimidines therapeutic use
Sulfonamides therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1545-5017
- Volume :
- 63
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Pediatric blood & cancer
- Publication Type :
- Academic Journal
- Accession number :
- 26375879
- Full Text :
- https://doi.org/10.1002/pbc.25733